Ridinilazole is an oral small molecule designed to selectively destroy C. difficile bacteria. Credit: AJC1.

UK-based Summit Therapeutics has started dosing in its Phase III clinical trial of antibiotic ridinilazole for the treatment of Clostridium difficile (C. difficile) infection (CDI).

Ridinilazole is an oral small molecule developed to selectively destroy C. difficile bacteria and preserve patients’ protective gut microbiome, as well as ensure sustained CDI cures.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase III programme consists of two trials that will evaluate the antibiotic’s superiority over the standard of care vancomycin as the primary endpoint.

The measure for superiority involves a combination of CDI cure and recurrence, sustained clinical response (SCR), within 30 days after treatment.

Secondary endpoints of the trials include cure and SCR at 60 days and 90 days following treatment. They will also evaluate additional endpoints such as the impact on the gut microbiome.

“We believe ridinilazole could be positioned as the drug of choice in the front-line treatment of CDI, which potentially provides patients with sustained cures.”

The trials also include health economic outcome measures such as readmission rates and length of hospital stay in order to support ridinilazole’s commercialisation, if approved.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Both the global, randomised, double-blind, active-controlled trials will be performed concurrently and will recruit around 680 patients each, at centres across North America, Latin America, Europe, Australia and Asia.

Top-line results from the Phase III programme are expected to be available in the second half of 2021.

Summit Therapeutics CEO Glyn Edwards said: “With positive results, we believe ridinilazole could be positioned as the drug of choice in the front-line treatment of CDI, which potentially provides patients with sustained cures and hospitals with compelling cost savings.”

Findings from a Phase II proof of concept trial demonstrated statistical superiority of ridinilazole in SCR rates, compared to vancomycin.

The antibiotic was also observed to be highly preserving of the gut microbiome.